Subaru Corporation announced today it had completed the acquisition of Toyota Motor shares, fulfilling the agreement between the two automakers. In September of 2019, Toyota increased its stake in Subaru from 16.83 percent to 20 percent, further strengthening their long-term partnership. Today Subaru acquired 8,973,700 shares in Toyota Motor Corporation, worth approximately $675 million.
What does it mean for Subaru and its customers?
In the announcement today, the Japanese automakers say, “Subaru will continue its efforts to advance further and strengthen the long-term relationship between the two companies.” What does it mean for the next-generation Forester, Outback, and Ascent models?
Photo credit: motor.es
Subaru and Toyota have been in partnership since 2005, which was formed to develop new cars like the BRZ and GR86 sports coupe. The partnership will now move forward and create a platform dedicated to battery electric vehicles (BEVs) and to jointly develop an all-elec
Aurinia Pharmaceuticals Inc.: Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH TSX:AUP) ( Aurinia or the Company ) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments – – Agreement includes royalties of up to 20 percent on net sales payable to Aurinia – Aurinia Pharmaceuticals Inc. today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral … – Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments –